Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5195 ARTÍCULOS , VIENDO DEL 751 AL 765

Exercise effects on brain and behavior in healthy mice, Alzheimer's disease and Parkinson's disease model-A systematic review and meta-analysis

da Costa Daniele TM, de Bruin PFC, de Matos RS, de Bruin GS, Maia Chaves C Junior, de Bruin VMS.

Behav Brain Res. 2020 Apr 6;383:112488. doi: 10.1016/j.bbr.2020.112488. Epub 2020 Jan 25.

Genetics of Parkinson's disease: An introspection of its journey towards precision medicine

Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB.

Neurobiol Dis. 2020 Apr;137:104782. doi: 10.1016/j.nbd.2020.104782. Epub 2020 Jan 25.

Neurobiology Research in Parkinson's Disease

Yasuhara T.

Int J Mol Sci. 2020 Jan 25;21(3):793. doi: 10.3390/ijms21030793.

Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease

Naoi M, Maruyama W, Shamoto-Nagai M.

J Neural Transm (Vienna). 2020 Feb;127(2):131-147. doi: 10.1007/s00702-020-02150-w. Epub 2020 Jan 28.

Physical Therapy for Freezing of Gait and Gait Impairments in Parkinson Disease: A Systematic Review

Rutz DG, Benninger DH.

PM R. 2020 Nov;12(11):1140-1156. doi: 10.1002/pmrj.12337. Epub 2020 May 19.

Intracerebral seeding of amyloid-β and tau pathology in mice: Factors underlying prion-like spreading and comparisons with α-synuclein

McAllister BB, Lacoursiere SG, Sutherland RJ, Mohajerani MH.

Neurosci Biobehav Rev. 2020 May;112:1-27. doi: 10.1016/j.neubiorev.2020.01.026. Epub 2020 Jan 26.

Advancement in the modelling and therapeutics of Parkinson's disease

Rai SN, Singh P.

J Chem Neuroanat. 2020 Mar;104:101752. doi: 10.1016/j.jchemneu.2020.101752. Epub 2020 Jan 26.

Synucleinopathies

Coon EA, Singer W.

Continuum (Minneap Minn). 2020 Feb;26(1):72-92. doi: 10.1212/CON.0000000000000819.

Beneficial effects of saffron (Crocus sativus L.) in ocular pathologies, particularly neurodegenerative retinal diseases

Fernández-Albarral JA, de Hoz R, Ramírez AI, López-Cuenca I, Salobrar-García E, Pinazo-Durán MD, Ramírez JM, Salazar JJ.

Neural Regen Res. 2020 Aug;15(8):1408-1416. doi: 10.4103/1673-5374.274325.

The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease

Goulding SR, Sullivan AM, O'Keeffe GW, Collins LM.

Neural Regen Res. 2020 Aug;15(8):1432-1436. doi: 10.4103/1673-5374.274327.

Bilateral vocal cord paralysis during emergence from general anesthesia in a patient with Parkinson's disease

Kim JI, Lee DH, Kim H.

Saudi J Anaesth. 2020 Jan-Mar;14(1):112-114. doi: 10.4103/sja.SJA_515_19. Epub 2020 Jan 6.

β-adrenoreceptors and the risk of Parkinson's disease

Hopfner F, Höglinger GU, Kuhlenbäumer G, Pottegård A, Wod M, Christensen K, Tanner CM, Deuschl G.

Lancet Neurol. 2020 Mar;19(3):247-254. doi: 10.1016/S1474-4422(19)30400-4. Epub 2020 Jan 27.

Differential role of triggering receptors expressed on myeloid cells 2 R47H in 3 neurodegenerative diseases based on a systematic review and meta-analysis

Zhang B, Li R, Zhang Y, Gao X.

Medicine (Baltimore). 2020 Jan;99(5):e18921. doi: 10.1097/MD.0000000000018921.

The potential neuromodulatory impact of subthalamic nucleus deep brain stimulation on Parkinson's disease progression

Szlufik S, Duszynska-Lysak K, Przybyszewski A, Laskowska-Levy I, Drzewinska A, Dutkiewicz J, Mandat T, Habela P, Koziorowski D.

J Clin Neurosci. 2020 Mar;73:150-154. doi: 10.1016/j.jocn.2019.12.059. Epub 2020 Jan 27.

Cell-free microRNAs in Parkinson's disease: potential biomarkers that provide new insights into disease pathogenesis

Doxakis E.

Ageing Res Rev. 2020 Mar;58:101023. doi: 10.1016/j.arr.2020.101023. Epub 2020 Jan 27.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias